Navigation Links
ALS Therapy Development Institute and Anida Pharma Partner to Investigate Potential Treatments for ALS
Date:9/10/2013

CAMBRIDGE, Mass., Sept. 10, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into a research partnership with Anida Pharma, Inc., to investigate a potential treatment for ALS, also known as Lou Gehrig's disease.   

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

Under the terms of the agreement with Anida, ALS TDI will test their lead compound, Neuroprotectin D1 (NPD1), in SOD1 mice for functional benefit.  NPD1, also referred to as Protectin D1 (PD1), activates resolution circuits to control neuroinflammation and prevent cell death, but also has trophic effects. To date, ALS TDI has conducted preclinical proof of concept studies with NPD1 in SOD1 mice. Through these pharmacodynamic studies, ALS TDI has demonstrated that it can deliver pharmacologically active levels of NPD1 to the central nervous system of the SOD1 mice, providing sufficient evidence to move it forward for additional preclinical testing.

"This partnership is yet another example of how our Institute, which is quite literally led by ALS patients and their families, identifies opportunities that otherwise may not get evaluated as a potential treatment for ALS," says Steve Perrin, Ph.D., CEO and CSO of ALS TDI. "It really is about moving as quickly as possible for patients today, and we are committed to doing just that through this partnership with Anida and the more than two dozen other programs our experienced drug development team is simultaneously working on at the Institute."

Anida marks the 12th venture philanthropy investment ALS TDI has made. Since 2007, ALS TDI has made more than $5 million of venture philanthropy investments in small biotechs like Anida Pharma. Previous venture philanthropy investments have been made with to-BBB, Neurotune, Regenesance, Glialogix, Aestus and others under confidential agreements.

"The possibility to partner with ALS TDI as a world-leading institute for ALS research is an extraordinary opportunity for Anida to accelerate its ALS drug development program towards the clinic. We believe that based on its unique property of multiple actions: regulating inflammation and cell death, but also exerting neurotrophic effects, NPD1 offers an exciting potential for the treatment of ALS," says Per Gjorstrup, M.D., Ph.D., President and CEO of Anida Pharma. 

About ALS
Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that leads to paralysis, due to the death of motor neurons in the spinal cord and brain. There is no known cure for the disease. About 5,000 people in the US are diagnosed with ALS each year; the incidence is similar to multiple sclerosis. However, with no effective treatment, the average patient survives only two to five years following diagnosis. There are about 30,000 people in the US diagnosed with ALS today. The worldwide population of ALS patients is estimated at 450,000.

About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) as soon as possible for patients today. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world's largest efforts to preclinically determine the efficacy of potential therapeutics, including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs. The world's first nonprofit biotech institute, ALS TDI employs 30 professional scientists, evaluates dozens of potential therapeutics each year and is currently executing a Phase IIA clinical trial of TDI-132 (Novartis' Gilenya®) in ALS patients.  Built by and for patients, the Cambridge, Massachusetts-based research institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, the Gladstone Institutes, MDA and RGK Foundation. For more information, please visit us online at www.als.net.

About Anida Pharma
Anida Pharma, Inc. is a biopharmaceutical company developing novel first-in-class therapies to treat amyotrophic lateral sclerosis (ALS; Lou Gehrig disease), Parkinson's disease, other central nervous system disorders, and hearing loss. Our therapeutic concept is based on activating the body's own homeostatic mechanisms to regulate inflammation, prevent cell death and stimulate tissue repair. Visit our website: www.anidapharma.com to learn more.

Media Contacts:
Mari Sullivan, ALS TDI, 617-441-7220, msullivan@als.net
Per Gjorstrup, Anida Pharma, 617-331-5033, pgjorstrup@anidapharma.com


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
3. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
6. Aperture Health, Inc. focuses in on IV Therapy Value Creation and the Merger and Acquisition Activities in the Home Infusion Therapy Sector.
7. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
8. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
9. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 The leader in accelerated orthodontics, ... is the recipient of the 2015 Townie Choice ... Class II medical device that speeds up orthodontic tooth ... pain often associated with treatment, AcceleDent was selected by ... annual Orthotown survey of the most reliable ...
(Date:2/9/2016)... The life of Dr. Jan Vilcek , celebrated immunologist ...  Twists of fate, combined with sheer grit, brought him from ... communist Czechoslovakia to New York City ... history by playing a key role in the development of ...  Dr. Vilcek brings readers along his improbable journey in his ...
(Date:2/9/2016)... The new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 ... that the North America continued to lead ... that translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... global anti-bacterial market is inclined towards North America ...
Breaking Medicine Technology:
(Date:2/10/2016)... Louis, Missouri (PRWEB) , ... February 10, 2016 ... ... 2016, in San Diego, will bring together more than 200 of the country’s ... healthcare for the future. , “The true benefit of the Forum is the ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Armune ... Apifiny® across their network of laboratory service centers across the country. Launched in ... aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests ...
(Date:2/10/2016)... Burnsville MN (PRWEB) , ... February 10, 2016 ... ... announced that it will attend the Ohio Safety Congress and Expo event March ... held at the Greater Columbus Convention Center. , As the longest running ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... – 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional ... Elite Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, Social ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Anxiety of ... since the start of Medicare Part D a decade ago, according to The ... from older adults on how they are coping with rapidly rising costs. “The ...
Breaking Medicine News(10 mins):